Steffen Flindt Nielsen
nicenielsen.bsky.social
Steffen Flindt Nielsen
@nicenielsen.bsky.social
Getting an early start on this years christmas decorations. My wife won’t let me put it up at home, so I guess I’ll bring it to work. #Nephsky #medsky
November 30, 2025 at 2:40 PM
Reposted by Steffen Flindt Nielsen
I think everyone is rightly sceptical if the large effect size, but given the high risk CVD risk and low cost/risk with fish oil, I feel it is too reactionary to just say “we need more trials”. We always need more trials, but they’re not likely to be forthcoming any time soon.
#NephSky
November 9, 2025 at 12:00 PM
Reposted by Steffen Flindt Nielsen
REMODEL is fantastic demonstration of what we can do with collaborative effort to perform what Kathy Tuttle calls mechanistic clinical trials!

Semaglutide provides kidney protection via improvements in inflammation and microvascular function. Lots of data to parse going forward. #KidneyWk
November 7, 2025 at 11:13 PM
Nothing works in dialysis - except fis oil. Truly amazing data from the PISCES. Should we begin perscribimg fish oil supplements to all our dialysis patients? In spite of my somewhat sceptical priors, I think the answer should be “yes” #NephSky #KidneyWk #nephrology
November 9, 2025 at 11:26 AM
Check out our new paper!
SGLT2i lower BP and the effect seems to be independent of baseline kidney function.

A clinically relevant point, and something to take in to consideration when prescribing.

#NephSky #MedSky #Hypertension #SGLT2i
#WeekendReads from the #AdvanceAccess section

Is the FLozin-BP effect modified by baseline GFR? An SR/MA

🔗 academic.oup.com/ajh/advance-... 🔒

#Hypertension #NephSky
August 31, 2025 at 6:16 AM
Reposted by Steffen Flindt Nielsen
#WeekendReads from the #AdvanceAccess section

Is the FLozin-BP effect modified by baseline GFR? An SR/MA

🔗 academic.oup.com/ajh/advance-... 🔒

#Hypertension #NephSky
August 30, 2025 at 7:25 PM